PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China.\', \'Sinovac Biotech, Beijing, China.\', \'National Institutes for Food and Drug Control, Beijing, China.\', \'Beijing Key Tech Statistics Technology, Beijing, China.\', \'Renqiu City Center for Disease Control and Prevention, Renqiu, Hebei, China.\', \'Sinovac Life Sciences, Beijing, China.\', \'Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China. Electronic address: yuliang_zh1@163.com.\', \'Sinovac Biotech, Beijing, China. Electronic address: yinwd@sinovac.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1473-3099(20)30987-710.1016/S1473-3099(20)30987-7
?:doi
?:hasPublicationType
?:journal
  • The Lancet. Infectious diseases
is ?:pmid of
?:pmid
?:pmid
  • 33548194
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33548194>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33548194>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all